MedeAnalytics Appoints Chris Lance as Chief Product Officer

News

MedeAnalytics Appoints Chris Lance as Chief Product Officer

2026-02-03 02:06 Last Updated At：02:20

RICHARDSON, Texas--(BUSINESS WIRE)--Feb 2, 2026--

MedeAnalytics, an enterprise healthcare performance company delivering AI-driven data, analytics, and SaaS solutions, today announced the appointment of Chris Lance as Chief Product Officer.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260202762973/en/

Lance brings more than 20 years of experience leading enterprise product and technology organizations, with a proven track record of building scalable platforms and high-performing portfolios that deliver measurable value for payers and providers. As Chief Product Officer, he will lead MedeAnalytics’ product vision, strategy, and execution across its Enterprise Healthcare Performance Cloud.

“Chris is a seasoned product leader with deep healthcare expertise and a strong ability to translate strategy into real-world impact,” said Steve Grieco, CEO of MedeAnalytics. “His experience building platform-based solutions and customer-informed products will be instrumental as we continue advancing our AI-native platform, built on our proprietary Health Fabric TM, to help customers move faster from insight to measurable impact.”

“I’m excited to join MedeAnalytics at what I believe is a true inflection point for healthcare,” said Lance. “By connecting trusted data with advanced analytics, AI, and intelligent workflows, MedeAnalytics is uniquely positioned to help organizations manage complexity, move faster, and achieve better outcomes. I look forward to working with the team to build products that turn data into intelligence, intelligence into action, and action into measurable healthcare performance across the ecosystem.”

Prior to joining MedeAnalytics, Lance served as Chief Product Officer at Avalon Healthcare Solutions, where he built high-performing teams, shaped enterprise and product strategy, and delivered innovative laboratory benefit management solutions. He also played a key leadership role in Avalon’s successful sale to WindRose Health Investors.

Before Avalon, Lance was Chief Product Officer at Edifecs, where he led a portfolio of market-leading products. During his tenure, he spearheaded the company’s transition to a cloud-first SaaS business model and, in partnership with the CEO and CFO, facilitated a successful multi-billion-dollar sale of the company to Cotiviti.

Earlier in his healthcare journey, Lance served as Chief Product Officer at Evolent Health, leading the development and delivery of the organization's health plan administration software and services portfolios. Prior to that, he rose through increasingly senior leadership roles at Change Healthcare, ultimately serving as Head of Product for a broad suite of payer financial management solutions, including Payment Integrity, Clinical Editing, Risk Adjustment, and Value-Based Payments. In these roles, he led multiple business transformation initiatives, including the adoption of platform-based operating models.

Lance began his career outside of healthcare, holding leadership roles across management consulting, general management, product management, sales, and engineering in the manufacturing and brewing industries. This diverse background has shaped his perspective on product leadership, customer value creation, and organizational transformation. He holds an MBA from the Olin School of Business at Washington University in St. Louis and a bachelor’s degree in industrial engineering from Purdue University.

Lance’s appointment underscores MedeAnalytics’ continued investment in product leadership and its commitment to delivering AI-driven, outcome-focused solutions that improve cost efficiency and MLR, strengthen revenue performance, and enhance care outcomes.

About MedeAnalytics

MedeAnalytics is an Enterprise Healthcare Performance company that delivers AI-driven, cloud-native solutions to help payers, providers, and employers measurably improve performance by reducing costs, improving MLR, increasing reimbursement, and elevating care quality. Its enterprise health data management platform—built on our proprietary Health Fabric™—unifies clinical, claims, financial, and social data into a single, scalable source of truth that fuels insights, action, and AI.

As the healthcare intelligence partner of choice for more than 30 years, MedeAnalytics combines comprehensive analytics, AI-powered workflows, and Strategic Advisory™ services to transform intelligence into accountable execution—delivering greater ROI across value-based care, risk and quality, utilization management, network optimization, population health, and revenue cycle operations.

MedeAnalytics empowers organizations to move faster from insight to impact with confidence and measurable results. To learn more, visit medeanalytics.com or follow MedeAnalytics on LinkedIn.

Stocks, gold and silver steady following wild swings overnight

NEW YORK (AP) — Wild swings that swept through financial markets overnight eased as trading headed westward to Wall Street on Monday. U.S. stocks rose following sharp drops in Asia and then gains in Europe, while gold and silver prices rallied back from severe earlier losses.

The S&P 500 added 0.7% and is on track to snap a three-day losing streak. The Dow Jones Industrial Average was up 506 points, or 1%, as of 1:05 p.m. Eastern time, and the Nasdaq composite was 0.9% higher.

Stocks of companies that make computer storage helped lead the market, adding to gains from last week following several profit reports that topped analysts' expectations. Airlines and cruise-ship operators were also strong, benefiting from a sharp easing of oil prices.

The center of the action in financial markets was again precious metals, where momentum has suddenly halted after gold’s price had roughly doubled in just 12 months.

Gold briefly dropped below $4,500 per ounce in the overnight hours, down more than $1,000 from its high point reached just last week. It has since pulled back to $4,702.70, down 0.9%.

Silver’s price has been on an even wilder ride recently, and it swung from a 9% loss overnight to a gain of 0.5%.

Gold and silver prices had been surging as investors looked for safer things to own amid a wide range of worries, including a Federal Reserve that may be set to become less independent, a U.S. stock market that critics say is expensive, threats of tariffs and heavy debt loads for governments worldwide.

Their prices cratered on Friday, including a 31.4% plunge for silver. Some on Wall Street saw it as a result of President Donald Trump’s nomination of Kevin Warsh as the next chair of the Fed. Warsh’s reputation as a former Fed governor may have raised expectations among some investors that he may keep interest rates high to fight against inflation, which would reduce the need to hide out in gold and silver for protection.

But many on Wall Street are also skeptical of that initial reading and say the expectation from Trump is likely that Warsh will cut interest rates, something the president has been demanding. That could give the economy a boost, but also inflation.

The Fed chair has a big influence on the economy and markets worldwide by helping to dictate where the U.S. central bank moves interest rates. That affects prices for all kinds of investments, as the Fed tries to keep the U.S. job market humming without letting inflation get out of control.

The recent swoons for gold and silver are likely more about the washout for some traders who had borrowed money to bet on metals’ prices continuing to soar, rather than about a wholesale change in expectations for demand for metals, according to Darrell Cronk, chief investment officer for Wealth & Investment Management at Wells Fargo

On Wall Street, Sandisk leaped 16.2% to lead the S&P 500. The data-storage company added to its 6.9% gain from Friday, after it reported stronger profit for the latest quarter than analysts expected. It credited demand created by the artificial-intelligence boom, among other things.

That helped offset a 0.6% drop for Nvidia, whose chips are powering much of the world’s move into AI technology. The losses were worse in Asia, where AI winners plunged. South Korea’s Kospi fell 5.3% from its record for its worst day in almost 10 months after chip company SK Hynix lost nearly 9%.

The Walt Disney Co. fell 6.9% even though the entertainment giant reported a stronger profit for the latest quarter than analysts expected. It warned of challenges keeping international visitors away from its U.S. theme parks, among other things.

Oil prices dropped more than 5% after Trump told reporters that Iran is “seriously talking to us.” It’s a potential signal of improving relations between the two countries, which could prevent a possible disruption to the global flow of oil.

That could mean less painful fuel bills for airlines and cruise ships. Carnival steamed 6.8% higher, and United Airlines climbed 5.5%.

In the bond market, Treasury yields edged higher after a report said that U.S. manufacturing grew last month, when economists were expecting a contraction. The yield on the 10-year Treasury erased an earlier dip and rose to 4.27%, up from 4.26% late Friday.

In stock markets abroad, European indexes rose roughly 1% following Asia’s washout. Japan’s Nikkei 225 fell 1.3%, while stocks fell 2.2% in Hong Kong and 2.5% in Shanghai.

AP Business Writers Matt Ott and Elaine Kurtenbach contributed.